TD Cowen analyst Marc Frahm downgraded Cardiff Oncology (NASDAQ: CRDF) from Buy to Hold.The analyst comments "Cardiff disclosed that onvansertib’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE